Farmas USA

Actc

Advanced Cell secures equity facility • 9:24 AM

Advanced Cell Technology (ACTC) enters into a $30M common stock purchase agreement with Lincoln Park Capital Fund LLC. Under the terms of the agreement, after the SEC declares its registration statement effective, ACTC will have the right to sell up to $30M worth of common shares to LPC over a 36-month period. The company issued common shares to LPC as payment for its commitment fee.
Read comments
ACTC price at time of publication: $0.07. Check ACTC price now »

Was this email forwarded to you? Learn more about Seeking Alpha Alerts here »

Focus Articles on ACTC
ACTC: Have The Stars Finally Aligned For A Breakout Year? by Biotech Research Group
The Inflection Point For Stem Cells: An Interview With Advanced Cell Technology's Management by BiotechScout
Advanced Cell Technology's Conference Call Recap And Analysis by JMY Investments
More News on ACTC
New leader at Antares Jun 24, 11:17 AM ET (Seeking Alpha)
Press Releases on ACTC
Advanced Cell Technology Secures $30 Million Equity Facility from Lincoln Park Capital (Business Wire)
Advanced Cell Technology, Inc. Announces Paul K. Wotton Ph.D. Recognized as Ernst & Young (EY) 2014 Entrepreneur of the Year™ for New Jersey Region (Business Wire)
Advanced Cell Technology Appoints Paul K. Wotton, Ph.D, President and Chief Executive Officer (Business Wire)
Related Articles on ACTC
StemCells, Inc: Expect Positive Trial Results To Drive The Stock Price Higher by JMY Investments
BioTime Joins Advanced Cell Technology In The AMD Race by JMY Investments
Neuralstem And Brainstorm Cell Therapeutics: The Race To Treat ALS by JMY Investments
StockTalk on ACTC: ACTC StockTalk | Twitter ACTC | Twitter $ACTC | ACTC Instablogs

Recent Market Alerts on ACTC: All news | Earnings | Dividends | M&A | On the move

Transcripts on ACTC
Advanced Cell Technology's CEO Discusses Q3 2013 Results - Earnings Call Transcript by SA Transcripts
Advanced Cell Technology's CEO Hosts 2013 Annual Shareholders Meeting (Transcript) by SA Transcripts
Advanced Cell Technology's CEO Discusses Q2 2013 Results - Earnings Call Transcript by SA Transcripts
Why are you receiving this? You subscribed to real-time News alerts at Seeking Alpha.
If this email was forwarded to you and you wish to receive this email directly, click here.

Manage your emails:
Get alerts on additional tickers and manage all your email alert choices here
I’m getting too many emails: manage your email alert choices
I’m no longer following ACTC: unsubscribe from all ACTC email alerts
This type of alert isn't helpful to me: unsubscribe from Breaking News alerts on ACTC

To ensure you receive these emails in the future, please add [email protected] to your address book, contacts or list of safe senders.

Prices in this email are BATS Last Sale quotes.

Sent by Seeking Alpha, 345 7th Ave. Suite 1400 New York, NY 10001

macro

La bolsa de Estados Unidos con ganancias tras conocerse el informe de empleo de la ADP. La creación de empleo no agrícola en EE.UU. sube mucho más de lo esperado en el mes de junio a 288.000 frente 212.000 esperado y 224.000 del mes anterior. Se trata de un mal dato para los mercados, ya que a pesar de que la cifra de empleo es muy buena, los inversores creen que podría llevar a la FED a adelantar la subida de tipos de interés prevista para la segunda mitad de 2015.La tasa de paro cae a 6,1% frente 6,3% esperado y anterior, mínimo de 6 años

actc

$ACTC - Advanced Cell Technology Secures $30 Million Equity Facility from Linc... -> http://stock-news.net/1309913 #stock #stocks #stockaction

parece entrada capital fondo lincoln Park capital

http://www.stockhouse.com/news/press-releases/2014/07/03/advanced-cell-technology-secures-30-million-equity-facility-from-lincoln-park

Modo móvil. Parece un buen movimiento a pesar d la dilucion ATM. Es poca pasta y no se hace efectiva hasta la subida a mercado organizado, que confirma por otra parte. investigo en media hora, de vuelta a casa.

mejor dilución con manos grandes ¿no?

ACTC

"Under the terms of the purchase agreement, ACT has agreed to file a registration statement with the U.S. Securities & Exchange Commission (“SEC”) covering the shares that may be issued to LPC under the agreement. After the SEC has declared effective the registration statement related to the transaction, the Company has the right over a 36-month period to sell up to $30,000,000 worth of shares of the Company’s Common Stock to LPC, subject to certain limitations and conditions set forth in the agreement. In consideration for entering into the agreement, the Company issued LPC shares of the Company’s Common Stock as a commitment fee."

-ACT controls the timing and amount of any sales of common stock to LPC at a known price;
-LPC cannot require ACT to make sales, but is obligated to make purchases as ACT directs in accordance with the terms of the agreement;
-There is no upper limit on the price per share that LPC could be obligated to pay for shares of common stock under the agreement; and
- There are no limitations on use of proceeds, financial covenants, restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages.

"LPC has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company’s Common Stock. The Purchase Agreement may be terminated by the Company(ACTC) at any time at the Company’s discretion without any cost to the Company"

The commitment fee paid to Lincoln Park is more than reasonable at some 250 basis points +/- of total $30 million committed. Of course Lincoln Park is thinking the 10 million shares will be worth substantially more in the near future. The fee is less than most entities pay to issue bonds or other debt. Good for ACTC, Good for Lincoln Park, Good for Shareholders and very timely event in total picture of events unfolding. Congratulations to entire Management Team.

"In consideration for entering into the Purchase Agreement, the Company issued to LPC 10,600,707 shares of the Company’s Common Stock as a commitment fee".

@ $0,07 = ± 742K for $30M = 2,4% fee

Comentarios:

"First, the terms are good for this type of funding, and second, we are close enough to the peer-reviewed publication (with legacy issues cleared up) and other positive catalysts, that we may be able to draw on it at a higher pps and be able to RS/uplist without needing to ask for an increase in AS before securing some kind of non-dilutive institutional funding."

"In other words, they are buying where you could have bought. You get it. Make them pay. The higher the share price the longer the shares last. Win win for everyone. "

"Many I think are concern where the money is coming from if not JV, I'll remind you

1) Peer review Publication of Phase I will be Enormous!
2) Phase II will be Enormous! You people do realize there are many on the sidelines who are not risk takers like me for example who invest in pre-clinical studies, then continue to buy during Phase I. There will be a huge amount of "buyers" who will look at data and invest during Phase II and lastly
3) Uplist will be Enormous! Again there are so many willing and ready to buy a stock on a more secured exchange."

"My gut is they want to JV but do not want to pay our price upfront. Great move..IMO..of Ted and Paul W. Longer JV suitor waits the more the price will go up. This will force them once the TLD is released."

Sevensuns, tenias razon
SNTA

si las dejas y miras en un año tiene pinta de dar dinero, pero hay que aguantar ese tiempo y sobre todo pasar a otro mercado.